Logo image of GRX

GABELLI HEALTHCARE & WELL (GRX) Stock Price, Quote, News and Overview

NYSE:GRX - New York Stock Exchange, Inc. - US36246K1034 - Currency: USD

10.07  -0.04 (-0.4%)

Fundamental Rating

2

Taking everything into account, GRX scores 2 out of 10 in our fundamental rating. GRX was compared to 0 industry peers in the Unkown industry. The financial health of GRX is average, but there are quite some concerns on its profitability. GRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRX had negative earnings in the past year.
In the past year GRX had a positive cash flow from operations.
GRX had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: GRX reported negative operating cash flow in multiple years.
GRX Yearly Net Income VS EBIT VS OCF VS FCFGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

1.2 Ratios

Industry RankSector Rank
ROA 1.53%
ROE 2.03%
ROIC N/A
ROA(3y)-2.24%
ROA(5y)3.37%
ROE(3y)-2.25%
ROE(5y)3.65%
ROIC(3y)N/A
ROIC(5y)N/A
GRX Yearly ROA, ROE, ROICGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20

1.3 Margins

In the last couple of years the Profit Margin of GRX has declined.
The Operating Margin and Gross Margin are not available for GRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 97.14%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-74.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRX Yearly Profit, Operating, Gross MarginsGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRX has less shares outstanding
GRX has less shares outstanding than it did 5 years ago.
GRX has a worse debt/assets ratio than last year.
GRX Yearly Shares OutstandingGRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
GRX Yearly Total Debt VS Total AssetsGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 1.90 indicates that GRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
GRX has a debt to FCF ratio of 1.74. This is a very positive value and a sign of high solvency as it would only need 1.74 years to pay back of all of its debts.
A Debt/Equity ratio of 0.32 indicates that GRX is not too dependend on debt financing.
Although GRX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.74
Altman-Z 1.9
ROIC/WACCN/A
WACCN/A
GRX Yearly LT Debt VS Equity VS FCFGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.00 indicates that GRX should not have too much problems paying its short term obligations.
GRX has a Quick Ratio of 2.00. This is a normal value and indicates that GRX is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 2
GRX Yearly Current Assets VS Current LiabilitesGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 100.10% over the past year.
The earnings per share for GRX have been decreasing by -72.17% on average. This is quite bad
Looking at the last year, GRX shows a decrease in Revenue. The Revenue has decreased by -1.94% in the last year.
The Revenue has been decreasing by -5.01% on average over the past years.
EPS 1Y (TTM)100.1%
EPS 3Y-72.17%
EPS 5YN/A
EPS Q2Q%-618.05%
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y4.21%
Revenue growth 5Y-5.01%
Sales Q2Q%-10.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRX Yearly Revenue VS EstimatesGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
GRX Yearly EPS VS EstimatesGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
GRX Price Earnings VS Forward Price EarningsGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 4.27
EV/EBITDA N/A
GRX Per share dataGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.93%, GRX is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.27, GRX pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.93%

5.2 History

GRX has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of GRX decreased in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years2
GRX Yearly Dividends per shareGRX Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

402.46% of the earnings are spent on dividend by GRX. This is not a sustainable payout ratio.
DP402.46%
EPS Next 2YN/A
EPS Next 3YN/A
GRX Yearly Income VS Free CF VS DividendGRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M
GRX Dividend Payout.GRX Dividend Payout, showing the Payout Ratio.GRX Dividend Payout.PayoutRetained Earnings

More info and screens

GABELLI HEALTHCARE & WELL

NYSE:GRX (2/24/2025, 8:04:00 PM)

10.07

-0.04 (-0.4%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners35.73%
Inst Owner Change-74.08%
Ins Owners1.86%
Ins Owner Change6.89%
Market Cap157.09M
Analysts0
Price TargetN/A
Short Float %0.08%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield 5.93%
Yearly Dividend0.6
Dividend Growth(5Y)N/A
DP402.46%
Div Incr Years0
Div Non Decr Years2
Ex-Date03-17 2025-03-17 (0.15)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.49
P/FCF 4.27
P/OCF 4.27
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)2.36
FCFY23.39%
OCF(TTM)2.36
OCFY23.39%
SpS0.27
BVpS12.86
TBVpS12.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.53%
ROE 2.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 97.14%
GM N/A
FCFM 877.09%
ROA(3y)-2.24%
ROA(5y)3.37%
ROE(3y)-2.25%
ROE(5y)3.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-74.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF 1.74
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 902.95%
Current Ratio 2
Quick Ratio 2
Altman-Z 1.9
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100.1%
EPS 3Y-72.17%
EPS 5YN/A
EPS Q2Q%-618.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y4.21%
Revenue growth 5Y-5.01%
Sales Q2Q%-10.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y268.27%
FCF growth 3Y-47.34%
FCF growth 5YN/A
OCF growth 1Y268.27%
OCF growth 3Y-47.34%
OCF growth 5YN/A